Abstract:IMPORTANCE: Whole-genome sequencing (WGS) is increasingly applied in clinical medicine and is expected to uncover clinically significant findings regardless of sequencing indication.OBJECTIVES: To examine coverage and concordance of clinically relevant genetic variation provided by WGS technologies; to quantitate inherited disease risk and pharmacogenomic findings in WGS data and resources required for their discovery and interpretation; and to evaluate clinical action prompted by WGS findings.DESIGN, SETTING, AND PARTICIPANTS: An exploratory study of 12 adult participants recruited at Stanford University Medical Center who underwent WGS between November 2011 and March 2012. A multidisciplinary team reviewed all potentially reportable genetic findings. Five physicians proposed initial clinical follow-up based on the genetic findings.MAIN OUTCOMES AND MEASURES: Genome coverage and sequencing platform concordance in different categories of genetic disease risk, person-hours spent curating candidate disease-risk variants, interpretation agreement between trained curators and disease genetics databases, burden of inherited disease risk and pharmacogenomic findings, and burden and interrater agreement of proposed clinical follow-up.RESULTS: Depending on sequencing platform, 10% to 19% of inherited disease genes were not covered to accepted standards for single nucleotide variant discovery. Genotype concordance was high for previously described single nucleotide genetic variants (99%-100%) but low for small insertion/deletion variants (53%-59%). Curation of 90 to 127 genetic variants in each participant required a median of 54 minutes (range, 5-223 minutes) per genetic variant, resulted in moderate classification agreement between professionals (Gross κ, 0.52; 95% CI, 0.40-0.64), and reclassified 69% of genetic variants cataloged as disease causing in mutation databases to variants of uncertain or lesser significance. Two to 6 personal disease-risk findings were discovered in each participant, including 1 frameshift deletion in the BRCA1 gene implicated in hereditary breast and ovarian cancer. Physician review of sequencing findings prompted consideration of a median of 1 to 3 initial diagnostic tests and referrals per participant, with fair interrater agreement about the suitability of WGS findings for clinical follow-up (Fleiss κ, 0.24; P < 001).CONCLUSIONS AND RELEVANCE: In this exploratory study of 12 volunteer adults, the use of WGS was associated with incomplete coverage of inherited disease genes, low reproducibility of detection of genetic variation with the highest potential clinical effects, and uncertainty about clinically reportable findings. In certain cases, WGS will identify clinically actionable genetic variants warranting early medical intervention. These issues should be considered when determining the role of WGS in clinical medicine.

Assessing reproducibility of inherited variants detected with short-read whole genome sequencing

Additional File 12 of Assessing Reproducibility of Inherited Variants Detected with Short-Read Whole Genome Sequencing

Additional File 10 of Assessing Reproducibility of Inherited Variants Detected with Short-Read Whole Genome Sequencing

Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing

Technical reproducibility of genotyping SNP arrays used in genome-wide association studies.

Hidden Biases in Germline Structural Variant Detection.

DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly

Systematic benchmark of state-of-the-art variant calling pipelines identifies major factors affecting accuracy of coding sequence variant discovery

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Increased Sensitivity of Diagnostic Mutation Detection by Re-analysis Incorporating Local Reassembly of Sequence Reads

Clinical Interpretation and Implications of Whole-Genome Sequencing

Whole Genome and Exome Sequencing Reference Datasets from a Multi-Center and Cross-Platform Benchmark Study

Assessing the efficacy of target adaptive sampling long-read sequencing through hereditary cancer patient genomes

Systematic dissection of biases in whole-exome and whole-genome sequencing reveals major determinants of coding sequence coverage

A powerful approach to identify replicable variants in genome-wide association studies

Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing

Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study

Improving somatic exome sequencing performance by biological replicates

Enhancing Variant Calling in Whole-Exome Sequencing Data Using Population-Matched Reference Genomes.

Curated variation benchmarks for challenging medically relevant autosomal genes

Inconsistency and Features of Single Nucleotide Variants Detected in Whole Exome Sequencing Versus Transcriptome Sequencing: A Case Study in Lung Cancer.